Physician profile
Robert A Sheely
NPI 1104895028
$6,148.65
in general payments reported to CMS, 2019-2025
44 companies · $932 in 2025
The $932 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $1,450 · 2021: $1,366 · 2022: $661 · 2023: $528 · 2024: $290 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $719.93 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $711.84 | 2021-2025 | Vraylar, Qulipta |
| Pfizer INC. | $367.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $330.90 | 2020-2025 | Airsupra, Farxiga |
| Allergan, INC. | $294.44 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.58 | 2020-2025 | Trintellix |
| Astellas Pharma US INC | $275.59 | 2019-2025 | Veozah |
| Lilly USA, LLC | $247.62 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $243.11 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.87 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $222.38 | 2019-2025 | Rybelsus, Tresiba, Ozempic |
| Biohaven Pharmaceuticals, INC. | $201.35 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.07 | 2019-2025 | Jardiance |
| Hikma Pharmaceuticals USA | $133.40 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $133.02 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sheely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.